Literature DB >> 27355232

The case for a national service for primary immune deficiency disorders in New Zealand.

Rohan Ameratunga1, Richard Steele, Anthony Jordan, Kahn Preece, Russell Barker, Maia Brewerton, Karen Lindsay, Jan Sinclair, Peter Storey, See-Tarn Woon.   

Abstract

Primary immune deficiency disorders (PIDs) are rare conditions for which effective treatment is available. It is critical these patients are identified at an early stage to prevent unnecessary morbidity and mortality. Treatment of these disorders is expensive and expert evaluation and ongoing management by a clinical immunologist is essential. Until recently there has been a major shortage of clinical immunologists in New Zealand. While the numbers of trained immunologists have increased in recent years, most are located in Auckland. The majority of symptomatic PID patients require life-long immunoglobulin replacement. Currently there is a shortage of subcutaneous and intravenous immunoglobulin (SCIG/IVIG) in New Zealand. A recent audit by the New Zealand Blood Service (NZBS) showed that compliance with indications for SCIG/IVIG treatment was poor in District Health Boards (DHBs) without an immunology service. The NZBS audit has shown that approximately 20% of annual prescriptions for SCIG/IVIG, costing $6M, do not comply with UK or Australian guidelines. Inappropriate use may have contributed to the present shortage of SCIG/IVIG necessitating importation of the product. This is likely to have resulted in a major unnecessary financial burden to each DHB. Here we present the case for a national service responsible for the tertiary care of PID patients and oversight for immunoglobulin use for primary and non-haematological secondary immunodeficiencies. We propose that other PIDs, including hereditary angioedema, are integrated into a national PID service. Ancillary services, including the customised genetic testing service, and research are also an essential component of an integrated national PID service and are described in this review. As we show here, a hub-and-spoke model for a national service for PIDs would result in major cost savings, as well as improved patient care. It would also allow seamless transition from paediatric to adult services.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27355232

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


  5 in total

Review 1.  Review: Diagnosing Common Variable Immunodeficiency Disorder in the Era of Genome Sequencing.

Authors:  Rohan Ameratunga; Klaus Lehnert; See-Tarn Woon; David Gillis; Vanessa L Bryant; Charlotte A Slade; Richard Steele
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

2.  Bronchiectasis is associated with delayed diagnosis and adverse outcomes in the New Zealand Common Variable Immunodeficiency Disorders cohort study.

Authors:  R Ameratunga; A Jordan; A Cavadino; S Ameratunga; T Hills; R Steele; M Hurst; B McGettigan; I Chua; M Brewerton; N Kennedy; W Koopmans; Y Ahn; R Barker; C Allan; P Storey; C Slade; A Baker; L Huang; S-T Woon
Journal:  Clin Exp Immunol       Date:  2021-04-12       Impact factor: 5.732

3.  Initial intravenous immunoglobulin doses should be based on adjusted body weight in obese patients with primary immunodeficiency disorders.

Authors:  Rohan Ameratunga
Journal:  Allergy Asthma Clin Immunol       Date:  2017-12-06       Impact factor: 3.406

4.  Comparison of Diagnostic Criteria for Common Variable Immunodeficiency Disorders (CVID) in the New Zealand CVID Cohort Study.

Authors:  Rohan Ameratunga; Hilary Longhurst; Richard Steele; See-Tarn Woon
Journal:  Clin Rev Allergy Immunol       Date:  2021-07-08       Impact factor: 8.667

5.  All Patients With Common Variable Immunodeficiency Disorders (CVID) Should Be Routinely Offered Diagnostic Genetic Testing.

Authors:  Rohan Ameratunga; Klaus Lehnert; See-Tarn Woon
Journal:  Front Immunol       Date:  2019-11-22       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.